Ahmed Abogamal
Ahmed Abogamal has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Bassel Elzorkany
Cairo University, Cairo, Egypt
5 shared publications - Nelly Ziade
Rheumatology Department, University Medical Center Hôtel-Dieu de France, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon
5 shared publications - Asal Adnan
Rheumatology Unit, Department of Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq
4 shared publications - Avin Maroof
University of Kurdistan Hewlêr-School of Medicine, Erbil, Iraq
4 shared publications - Chafika Haouichat
Rheumatology Department, Djilali Bounaama University Hospital, Khemis Miliana, Douera, Algeria
4 shared publications - Faiq Isho Gorial
Rheumatology Unit, Department of Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq
4 shared publications
Latest Publications
- 10 January 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (2) , 967-977
Do the Psoriatic Arthritis Impact of Disease’s cutoffs vary across ethnicities? Insights from the TACTIC initiative
Objective To establish cutoff values for the Arabic version of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire and examine their applicability across different cultural and ethnic backgrounds in Arab countries. Methods This study is a sub-analysis of the TACTIC initiative, a multicentric, multinational cross-sectional study. A total of 553 patients diagnosed with PsA from 13 Arab countries were included. Demographic and clinical data were collected, and disease activity was assessed using the Disease Activity in Psoriatic Arthritis (DAPSA) score. Psychometric scores, including the Patient Global Assessment (PGA), Health Assessment Questionnaire (HAQ), Patient Health Questionnaire (PHQ-4), and Fibromyalgia Screening Tool (FiRST), were also evaluated. PsAID thresholds were determined using Ward’s method and the “Anchor-based Threshold Determination” according to changes in DAPSA categories. Results Five hundred fifty-three patients were included in the current analysis, with 59.0% being female. The mean age of the patients was 45.5 years (SD 13.15), and the mean disease duration was 8.8 years (SD 7.3). The mean PsAID was 3.8 (SD 2.3), and the mean DAPSA was 19.3 (SD 16.1). Two clusters were identified based on PsAID levels. Cluster 1 (n = 315) had a mean PsAID of 2.15, while cluster 2 (n = 238) had a mean PsAID of 6.12. Using Ward’s method, the cutoff value was established at 4.1. A strong positive correlation was observed between DAPSA and PsAID scores (r = 0.718, p < 0.001). The anchor-based threshold analysis—based on shifts in DAPSA disease activity categories—identified a cutoff value of 3.8, which demonstrated good sensitivity and specificity in distinguishing between different levels of disease activity with an AUC of 0.83. Conclusion The Arabic PsAID threshold was found to be consistent with the internationally established value of 4. These identified cutoff points can serve as valuable tools for evaluating the impact of psoriatic arthritis on patients' quality of life. Moreover, they can help guide more personalized treatment strategies across diverse populations and ethnic groups. Key Points • This study established cutoff values for the Arabic version of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, confirming their alignment with international thresholds. • Analysis of 553 patients from 13 Arab countries demonstrated robust correlations between PsAID and disease activity measures, with an optimal cutoff around 4. • These thresholds provide reliable tools for assessing disease impact and can support personalized treatment strategies across diverse Arab populations.
- 10 January 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (2) , 967-977
Do the Psoriatic Arthritis Impact of Disease’s cutoffs vary across ethnicities? Insights from the TACTIC initiative
Objective To establish cutoff values for the Arabic version of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire and examine their applicability across different cultural and ethnic backgrounds in Arab countries. Methods This study is a sub-analysis of the TACTIC initiative, a multicentric, multinational cross-sectional study. A total of 553 patients diagnosed with PsA from 13 Arab countries were included. Demographic and clinical data were collected, and disease activity was assessed using the Disease Activity in Psoriatic Arthritis (DAPSA) score. Psychometric scores, including the Patient Global Assessment (PGA), Health Assessment Questionnaire (HAQ), Patient Health Questionnaire (PHQ-4), and Fibromyalgia Screening Tool (FiRST), were also evaluated. PsAID thresholds were determined using Ward’s method and the “Anchor-based Threshold Determination” according to changes in DAPSA categories. Results Five hundred fifty-three patients were included in the current analysis, with 59.0% being female. The mean age of the patients was 45.5 years (SD 13.15), and the mean disease duration was 8.8 years (SD 7.3). The mean PsAID was 3.8 (SD 2.3), and the mean DAPSA was 19.3 (SD 16.1). Two clusters were identified based on PsAID levels. Cluster 1 (n = 315) had a mean PsAID of 2.15, while cluster 2 (n = 238) had a mean PsAID of 6.12. Using Ward’s method, the cutoff value was established at 4.1. A strong positive correlation was observed between DAPSA and PsAID scores (r = 0.718, p < 0.001). The anchor-based threshold analysis—based on shifts in DAPSA disease activity categories—identified a cutoff value of 3.8, which demonstrated good sensitivity and specificity in distinguishing between different levels of disease activity with an AUC of 0.83. Conclusion The Arabic PsAID threshold was found to be consistent with the internationally established value of 4. These identified cutoff points can serve as valuable tools for evaluating the impact of psoriatic arthritis on patients' quality of life. Moreover, they can help guide more personalized treatment strategies across diverse populations and ethnic groups. Key Points • This study established cutoff values for the Arabic version of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, confirming their alignment with international thresholds. • Analysis of 553 patients from 13 Arab countries demonstrated robust correlations between PsAID and disease activity measures, with an optimal cutoff around 4. • These thresholds provide reliable tools for assessing disease impact and can support personalized treatment strategies across diverse Arab populations.
- 8 December 2025
- Published by Springer Nature in Rheumatology International
- Vol. 46 (1) , 6
Impact of concomitant fibromyalgia on patient-reported outcomes and inflammatory markers in psoriatic arthritis: a multinational cross-sectional study
- 8 December 2025
- Published by Springer Nature in Rheumatology International
- Vol. 46 (1) , 6
Impact of concomitant fibromyalgia on patient-reported outcomes and inflammatory markers in psoriatic arthritis: a multinational cross-sectional study
- Open Access
- 14 September 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Impact of dactylitis and enthesitis resolution on disease control in guselkumab-treated psoriatic arthritis patients with TNFi-IR: COSMOS post hoc analysis
Objective: To evaluate guselkumab efficacy on dactylitis resolution (DR) and enthesitis resolution (ER), and their impact on subsequent disease control, in patients with active psoriatic arthritis (PsA) and prior inadequate response to tumour necrosis factor inhibitors (TNFi-IR). Methods: In the Phase IIIb COSMOS trial, 285 adults with TNFi-IR PsA were randomized (2:1) to receive guselkumab 100 mg or placebo at Week (W)0, W4, then every 8 weeks until W44. The Dactylitis Severity Score (DSS) and Leeds Enthesitis Index (LEI) assessed dactylitis and enthesitis, respectively. This post hoc analysis evaluated associations between W24 DR or ER and W48 achievement of stringent disease control measures using logistic regression. Results: At baseline, 103/285 (36.1%) patients had dactylitis (DSS ≥ 1) and 190/285 (66.7%) had enthesitis (LEI ≥ 1). Patients with dactylitis were more likely to have enthesitis, more joint (SJC/DAPSA) and skin involvement, higher PGA score and lower BMI vs those without dactylitis. Patients with enthesitis were more likely to be female, and have dactylitis, more joints affected (SJC/TJC/DAPSA) and worse physical functioning (HAQ-DI/SF-36 PCS) vs those without enthesitis. Greater proportions of guselkumab- vs placebo-treated patients achieved DR/ER (W24: 44.8%/39.7% vs 25.0%/18.8%); rates increased through W48 among guselkumab-randomized patients (67.2%/55.6%). W24 resolution was associated with W48 achievement of stringent measures, including ACR50/70, DAPSA LDA/remission, PASI100, PASDAS LDA/VLDA and MDA/VLDA (odds ratios: DR, 3.28–13.38; ER, 2.88–6.09). Conclusion: Guselkumab treatment resulted in high DR/ER rates through W48 in TNFi-IR PsA patients. W24 DR/ER was associated with W48 disease control, providing valuable insights for clinical decision-making based on W24 treatment responses.
- 14 September 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Open AccessImpact of dactylitis and enthesitis resolution on disease control in guselkumab-treated psoriatic arthritis patients with TNFi-IR: COSMOS post hoc analysis
Objective: To evaluate guselkumab efficacy on dactylitis resolution (DR) and enthesitis resolution (ER), and their impact on subsequent disease control, in patients with active psoriatic arthritis (PsA) and prior inadequate response to tumour necrosis factor inhibitors (TNFi-IR). Methods: In the Phase IIIb COSMOS trial, 285 adults with TNFi-IR PsA were randomized (2:1) to receive guselkumab 100 mg or placebo at Week (W)0, W4, then every 8 weeks until W44. The Dactylitis Severity Score (DSS) and Leeds Enthesitis Index (LEI) assessed dactylitis and enthesitis, respectively. This post hoc analysis evaluated associations between W24 DR or ER and W48 achievement of stringent disease control measures using logistic regression. Results: At baseline, 103/285 (36.1%) patients had dactylitis (DSS ≥ 1) and 190/285 (66.7%) had enthesitis (LEI ≥ 1). Patients with dactylitis were more likely to have enthesitis, more joint (SJC/DAPSA) and skin involvement, higher PGA score and lower BMI vs those without dactylitis. Patients with enthesitis were more likely to be female, and have dactylitis, more joints affected (SJC/TJC/DAPSA) and worse physical functioning (HAQ-DI/SF-36 PCS) vs those without enthesitis. Greater proportions of guselkumab- vs placebo-treated patients achieved DR/ER (W24: 44.8%/39.7% vs 25.0%/18.8%); rates increased through W48 among guselkumab-randomized patients (67.2%/55.6%). W24 resolution was associated with W48 achievement of stringent measures, including ACR50/70, DAPSA LDA/remission, PASI100, PASDAS LDA/VLDA and MDA/VLDA (odds ratios: DR, 3.28–13.38; ER, 2.88–6.09). Conclusion: Guselkumab treatment resulted in high DR/ER rates through W48 in TNFi-IR PsA patients. W24 DR/ER was associated with W48 disease control, providing valuable insights for clinical decision-making based on W24 treatment responses.
- 12 March 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (4) , 1-13
Discordance between patient and physician global assessments of psoriatic arthritis activity: an observational study in 13 Arab countries
Discordance between physicians and patients in assessing psoriatic arthritis (PsA) activity is common and might impact treatment adherence and decision-making. Cultural and belief systems may influence this discordance. This study aimed to assess the extent of patient-physician discordance in PsA in Arab countries and its association with demographic and disease characteristics.The TACTIC study was a cross-sectional observational study across 13 Arab countries in 2022. Patient and physician global assessments (PGA, PhGA) of disease activity (0–10 scale) were collected, along with demographic and disease data, Disease Activity in Psoriatic Arthritis (DAPSA), and Psoriatic Arthritis Impact of Disease (PsAID). Discordance was defined as an absolute difference of |PGA-PhGA|> 2. Its association with patient characteristics was analyzed through multivariable multinomial logistic regression. In 538 patients (317 females, 58.9%), with a mean age of 45.5 ± 13.2 years and PsA duration of 8.8 ± 7.3 years, the disease was moderately active (mean DAPSA 19.3 ± 16.1; mean PsAID 3.86 ± 2.33). Mean PGA was higher than mean PhGA (4.7 ± 2.5 versus 4.0 ± 2.4, p < 0.001) with an absolute difference of 1.30 ± 1.41 and a high correlation between global assessments (r = 0.74). Discordance was infrequent, occurring in 84 patients (15.6%), and was mostly due to higher PGA (70/84, 83.3%). Discordance (one-point increase) was associated with a lower PhGA (Odds ratio (OR) 3.03 [95%CI 2.18–4.22]), positive fibromyalgia screening (OR 1.28 [95%CI 1.03–1.58]), higher DAPSA (OR 1.16 [95%CI 1.03–1.09]), and higher PsAID scores (OR 2.63 [95%CI 1.96–3.54]). Discordance was primarily identified in patients with moderate disease activity. Discordance between PGA and PhGA was infrequent in Arab countries, suggesting strong patient-physician alignment. Expectations and disease perceptions may play a role in this discordance.
- 12 March 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (4) , 1-13
Discordance between patient and physician global assessments of psoriatic arthritis activity: an observational study in 13 Arab countries
Discordance between physicians and patients in assessing psoriatic arthritis (PsA) activity is common and might impact treatment adherence and decision-making. Cultural and belief systems may influence this discordance. This study aimed to assess the extent of patient-physician discordance in PsA in Arab countries and its association with demographic and disease characteristics.The TACTIC study was a cross-sectional observational study across 13 Arab countries in 2022. Patient and physician global assessments (PGA, PhGA) of disease activity (0–10 scale) were collected, along with demographic and disease data, Disease Activity in Psoriatic Arthritis (DAPSA), and Psoriatic Arthritis Impact of Disease (PsAID). Discordance was defined as an absolute difference of |PGA-PhGA|> 2. Its association with patient characteristics was analyzed through multivariable multinomial logistic regression. In 538 patients (317 females, 58.9%), with a mean age of 45.5 ± 13.2 years and PsA duration of 8.8 ± 7.3 years, the disease was moderately active (mean DAPSA 19.3 ± 16.1; mean PsAID 3.86 ± 2.33). Mean PGA was higher than mean PhGA (4.7 ± 2.5 versus 4.0 ± 2.4, p < 0.001) with an absolute difference of 1.30 ± 1.41 and a high correlation between global assessments (r = 0.74). Discordance was infrequent, occurring in 84 patients (15.6%), and was mostly due to higher PGA (70/84, 83.3%). Discordance (one-point increase) was associated with a lower PhGA (Odds ratio (OR) 3.03 [95%CI 2.18–4.22]), positive fibromyalgia screening (OR 1.28 [95%CI 1.03–1.58]), higher DAPSA (OR 1.16 [95%CI 1.03–1.09]), and higher PsAID scores (OR 2.63 [95%CI 1.96–3.54]). Discordance was primarily identified in patients with moderate disease activity. Discordance between PGA and PhGA was infrequent in Arab countries, suggesting strong patient-physician alignment. Expectations and disease perceptions may play a role in this discordance.
- 18 March 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (5) , 885-899
Is the patient-perceived impact of psoriatic arthritis a global concept? An international study in 13 Arab countries (TACTIC study)
The Psoriatic Arthritis Impact of Disease (PsAID-12) questionnaire, a recommended measure of patient-reported impact for psoriatic arthritis (PsA), was initially developed in Europe and may lack universal validity. Recognizing the need for a culturally appropriate tool for Arab patients, this study aimed to TranslAte, CulTurally adapt, and validate the PsAID in ArabIC (TACTIC). The PsAID-12 was translated into Arabic using a rigorous process of double translation, back-translation, and cognitive debriefing. The Arabic version was then validated through a study conducted in 13 Arab countries in 2022. Participants were consecutive literate adult patients diagnosed with PsA and fulfilling the CASPAR criteria. Collected data included PsAID-12, disease activity, and legacy patient-reported outcomes. Psychometric properties, such as internal consistency, construct validity, and test–retest reliability, were examined. Factors associated with high PsAID-12 total scores (> 4) were explored using multivariable binary logistic regression. A culturally adapted Arabic PsAID-12 questionnaire was achieved with minor rephrasing. The validation study included 554 patients from 13 countries (mean age 45 years, 59% females), with a mean PsAID score of 3.86 (SD 2.33). The Arabic PsAID-12 demonstrated excellent internal consistency (Cronbach’s α = 0.95), and correlations with other measures ranged from 0.63 to 0.78. Test–retest reliability (N = 138 patients) was substantial (intraclass correlation coefficient, ICC 0.90 [0.86–0.93]; Cohen’s kappa 0.80). Factors associated with a high PsAID score were disability (odds ratio, OR 3.15 [2.03–4.89]), depression (OR 1.56 [1.35–1.81]), widespread pain (OR 1.31 [1.12–1.53]), and disease activity (OR 1.29 [1.13–1.47]). Pain and fatigue were identified as the most impactful PsAID-12 domains for PsA patients. The Arabic PsAID is a valid and reliable measure that reflects the priorities of patients with PsA. PsAID scores correlated with disease activity and legacy outcome measures, as expected, indicating PsAID is a consistent measure of PsA impact across cultures. These findings highlight the potential of the Arabic PsAID in improving the care provided to Arabic-speaking patients worldwide.
- 18 March 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (5) , 885-899
Is the patient-perceived impact of psoriatic arthritis a global concept? An international study in 13 Arab countries (TACTIC study)
The Psoriatic Arthritis Impact of Disease (PsAID-12) questionnaire, a recommended measure of patient-reported impact for psoriatic arthritis (PsA), was initially developed in Europe and may lack universal validity. Recognizing the need for a culturally appropriate tool for Arab patients, this study aimed to TranslAte, CulTurally adapt, and validate the PsAID in ArabIC (TACTIC). The PsAID-12 was translated into Arabic using a rigorous process of double translation, back-translation, and cognitive debriefing. The Arabic version was then validated through a study conducted in 13 Arab countries in 2022. Participants were consecutive literate adult patients diagnosed with PsA and fulfilling the CASPAR criteria. Collected data included PsAID-12, disease activity, and legacy patient-reported outcomes. Psychometric properties, such as internal consistency, construct validity, and test–retest reliability, were examined. Factors associated with high PsAID-12 total scores (> 4) were explored using multivariable binary logistic regression. A culturally adapted Arabic PsAID-12 questionnaire was achieved with minor rephrasing. The validation study included 554 patients from 13 countries (mean age 45 years, 59% females), with a mean PsAID score of 3.86 (SD 2.33). The Arabic PsAID-12 demonstrated excellent internal consistency (Cronbach’s α = 0.95), and correlations with other measures ranged from 0.63 to 0.78. Test–retest reliability (N = 138 patients) was substantial (intraclass correlation coefficient, ICC 0.90 [0.86–0.93]; Cohen’s kappa 0.80). Factors associated with a high PsAID score were disability (odds ratio, OR 3.15 [2.03–4.89]), depression (OR 1.56 [1.35–1.81]), widespread pain (OR 1.31 [1.12–1.53]), and disease activity (OR 1.29 [1.13–1.47]). Pain and fatigue were identified as the most impactful PsAID-12 domains for PsA patients. The Arabic PsAID is a valid and reliable measure that reflects the priorities of patients with PsA. PsAID scores correlated with disease activity and legacy outcome measures, as expected, indicating PsAID is a consistent measure of PsA impact across cultures. These findings highlight the potential of the Arabic PsAID in improving the care provided to Arabic-speaking patients worldwide.
- 18 April 2023
- Published by Elsevier in Joint Bone Spine
- Vol. 90 (5) , 105579
What is the best referral strategy for axial spondyloarthritis? A prospective multicenter study in patients with suspicious chronic low back pain
- 18 April 2023
- Published by Elsevier in Joint Bone Spine
- Vol. 90 (5) , 105579
What is the best referral strategy for axial spondyloarthritis? A prospective multicenter study in patients with suspicious chronic low back pain
- 1 November 2022
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 50 (2) , 265-278
Management of Dactylitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
Objective: This literature review aimed to identify the most efficacious current interventions for dactylitis and provide up-to-date scientific evidence to support the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommendations on the management of psoriatic arthritis.Methods: Original articles published from 2013 to 2020, registered in MEDLINE, Embase, and Cochrane Library, describing interventional trials and reporting dactylitis-related outcomes were included. The 20 members of the GRAPPA dactylitis group were divided into 9 subgroups according to treatment, and members of each group independently extracted data from articles/abstracts corresponding to their group by using a standardized data extraction form.Results: Forty-nine publications were analyzed, representing 40 randomized clinical trials (RCTs) and including 16,752 patients. Dactylitis was assessed as a secondary outcome in 97.5% of these trials and more than 40% of RCTs did not employ a specific dactylitis measure or instrument.Conclusion: The emergence of agents with novel mechanisms of action in recent years, such as interleukin 17 (IL-17), IL-12/23, IL-23, and Janus kinase inhibitors, has significantly expanded the available treatment options for dactylitis. This article points out the lack of consensus regarding dactylitis assessment and the paucity of data concerning the effect of local steroid injections, nonsteroidal antiinflammatory drugs, and conventional disease-modifying antirheumatic drugs. Clinical trials evaluating the effect of these traditional and low-cost medications used to treat dactylitis should be encouraged.
- 1 November 2022
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 50 (2) , 265-278
Management of Dactylitis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
Objective: This literature review aimed to identify the most efficacious current interventions for dactylitis and provide up-to-date scientific evidence to support the 2021 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommendations on the management of psoriatic arthritis.Methods: Original articles published from 2013 to 2020, registered in MEDLINE, Embase, and Cochrane Library, describing interventional trials and reporting dactylitis-related outcomes were included. The 20 members of the GRAPPA dactylitis group were divided into 9 subgroups according to treatment, and members of each group independently extracted data from articles/abstracts corresponding to their group by using a standardized data extraction form.Results: Forty-nine publications were analyzed, representing 40 randomized clinical trials (RCTs) and including 16,752 patients. Dactylitis was assessed as a secondary outcome in 97.5% of these trials and more than 40% of RCTs did not employ a specific dactylitis measure or instrument.Conclusion: The emergence of agents with novel mechanisms of action in recent years, such as interleukin 17 (IL-17), IL-12/23, IL-23, and Janus kinase inhibitors, has significantly expanded the available treatment options for dactylitis. This article points out the lack of consensus regarding dactylitis assessment and the paucity of data concerning the effect of local steroid injections, nonsteroidal antiinflammatory drugs, and conventional disease-modifying antirheumatic drugs. Clinical trials evaluating the effect of these traditional and low-cost medications used to treat dactylitis should be encouraged.
- Open Access
- 18 April 2019
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 16 (8) , 1395
Classroom Furniture Mismatch and Back Pain Among Adolescent School-Children in Abha City, Southwestern Saudi Arabia
Objective: To explore the potential classroom furniture mismatch with students’ anthropometric measurements and back pain related to sitting for extended periods. Methods: This cross-sectional study was carried out on all twelve male and female intermediate and secondary schools located in Abha city. Anthropometric and classroom furniture measurements were assessed, and the mismatch was determined using standardized methods. Students were also screened for back pain related to long sitting at school. Results: A total number of 879 students was selected. The study revealed seat height mismatch in both intermediate, and secondary school of 84.3%, and 75.6%, respectively. Seat depth mismatch was 74.0% in intermediate schools and reached 84.5% in secondary schools. The desk height was improper for 94.1%, and 82.3% of students in intermediate, and secondary schools, respectively. The levels of mismatch differ significantly by grade level and gender. A prevalence of 10.8% of back pain related to long sitting at school was found. In multivariable logistic regression, males, intermediate school children, and the presence of buttock-popliteal length/seat depth mismatch were significantly associated with pain. On the other hand, practicing exercise was a significant protective factor. Conclusions: There is a prevalent mismatch between students’ dimensions and existing schools’ furniture. School furniture providers should take in consideration the average Saudi students’ dimensions, while designing school furniture especially for males, and at intermediate schools, or provide schools with adjustable seats and desks.
- 18 April 2019
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 16 (8) , 1395
Open AccessClassroom Furniture Mismatch and Back Pain Among Adolescent School-Children in Abha City, Southwestern Saudi Arabia
Objective: To explore the potential classroom furniture mismatch with students’ anthropometric measurements and back pain related to sitting for extended periods. Methods: This cross-sectional study was carried out on all twelve male and female intermediate and secondary schools located in Abha city. Anthropometric and classroom furniture measurements were assessed, and the mismatch was determined using standardized methods. Students were also screened for back pain related to long sitting at school. Results: A total number of 879 students was selected. The study revealed seat height mismatch in both intermediate, and secondary school of 84.3%, and 75.6%, respectively. Seat depth mismatch was 74.0% in intermediate schools and reached 84.5% in secondary schools. The desk height was improper for 94.1%, and 82.3% of students in intermediate, and secondary schools, respectively. The levels of mismatch differ significantly by grade level and gender. A prevalence of 10.8% of back pain related to long sitting at school was found. In multivariable logistic regression, males, intermediate school children, and the presence of buttock-popliteal length/seat depth mismatch were significantly associated with pain. On the other hand, practicing exercise was a significant protective factor. Conclusions: There is a prevalent mismatch between students’ dimensions and existing schools’ furniture. School furniture providers should take in consideration the average Saudi students’ dimensions, while designing school furniture especially for males, and at intermediate schools, or provide schools with adjustable seats and desks.
- Open Access
- 7 March 2019
- Published by Springer Nature in Advances in Rheumatology
- Vol. 59 (1) , 11
A single simple position for ultrasound assessment of both common extensor and common flexor origin at the elbow
Is to evaluate the simplicity of 90° flexion/neutral position for ultrasonography assessment of both common extensor and common flexor origins in comparison with the standard position. A standard questionnaire was distributed on 50 trainees, rheumatologists with No previous experience or training in ultrasonography. (They) were attending musculoskeletal training workshops at AL-Azhar rheumatology department musculoskeletal ultrasonography unit in 2016. Each participant then (was) asked to practice US examination of both common extensor and common flexor origins in both positions and then fill four questionnaires, two (of which are) for common flexor and (the other) two (are) for the common extensor origins, in the standard and the other proposed single position. Each questionnaire (whose) answer was graded on scale from 0 to 10, includes the following points: • Time needed to examine the tendon in minutes, • Difficulty in maintaining the probe contact to the skin, • Difficulty in getting good image of the tendon, • The overall impression of simplicity. Descriptive analysis of the questionnaire results shows that the participants favors the single position in all questionnaire parameters. Comparing means of the four questionnaire parameters in both positions shows highly significant difference in the four parameters at the level of both common flexor and extensor origins in favor of the single position as p > 0.005. The 90 degree flexion/neutral position appears to be simpler than the standard position for ultrasonography assessment of common extensor and common flexor tendons at the elbow.
- 7 March 2019
- Published by Springer Nature in Advances in Rheumatology
- Vol. 59 (1) , 11
Open AccessA single simple position for ultrasound assessment of both common extensor and common flexor origin at the elbow
Is to evaluate the simplicity of 90° flexion/neutral position for ultrasonography assessment of both common extensor and common flexor origins in comparison with the standard position. A standard questionnaire was distributed on 50 trainees, rheumatologists with No previous experience or training in ultrasonography. (They) were attending musculoskeletal training workshops at AL-Azhar rheumatology department musculoskeletal ultrasonography unit in 2016. Each participant then (was) asked to practice US examination of both common extensor and common flexor origins in both positions and then fill four questionnaires, two (of which are) for common flexor and (the other) two (are) for the common extensor origins, in the standard and the other proposed single position. Each questionnaire (whose) answer was graded on scale from 0 to 10, includes the following points: • Time needed to examine the tendon in minutes, • Difficulty in maintaining the probe contact to the skin, • Difficulty in getting good image of the tendon, • The overall impression of simplicity. Descriptive analysis of the questionnaire results shows that the participants favors the single position in all questionnaire parameters. Comparing means of the four questionnaire parameters in both positions shows highly significant difference in the four parameters at the level of both common flexor and extensor origins in favor of the single position as p > 0.005. The 90 degree flexion/neutral position appears to be simpler than the standard position for ultrasonography assessment of common extensor and common flexor tendons at the elbow.
- Open Access
- 31 December 2018
- Published by Bentham Science Publishers Ltd. in The Open Rheumatology Journal
- Vol. 12 (1) , 323-331
Clinical Efficacy and Safety of Leflunomide in Egyptian Patients with Active Rheumatoid Arthritis: CLEAR Interim Results
Background: Worldwide, leflunomide is a commonly used Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It can be used as a monotherapy or in combination with other DMARDs to inhibit the production of inflammatory cells and accordingly reduce inflammation. Objectives: CLEAR is a multi-centric study that aims to assess the clinical efficacy and safety of leflunomide as first-line and/or add-on therapy to other DMARDs with or without steroids in Egyptian patients with active Rheumatoid Arthritis (RA). Methods: Egyptian patients with active RA for whom leflunomide was prescribed at physicians’ discretion were observed for 12 weeks. Clinical Disease Activity Index (CDAI) score, and Health Assessment Questionnaire Disability Index (HAQ-DI) score were acquired thrice during this period. This study was registered on clinicaltrials.gov (NCT03599986). Results: Interim analysis of the data collected from 337 patients (in 21 centers) showed a statistically significant decrease in the mean total CDAI score throughout the first 12 weeks of treatment (pp<0.001) was also observed in HAQ-DI, as the mean ±SD score decreased from 1.46 ±0.69 at baseline to reach 0.67 ±0.54 at week 12 (% reduction: 56.11 ±27.59). Conclusion: Results of the interim analysis suggest that treatment of Egyptian patients with active RA with leflunomide (as first-line and/or add-on therapy to other DMARDs with or without steroids) for 12 weeks may be effective in terms of CDAI score and HAQ-DI score reduction and may offer an alternative for patients who experienced resistance, inadequate response or intolerance to other DMARDs.
- 31 December 2018
- Published by Bentham Science Publishers Ltd. in The Open Rheumatology Journal
- Vol. 12 (1) , 323-331
Open AccessClinical Efficacy and Safety of Leflunomide in Egyptian Patients with Active Rheumatoid Arthritis: CLEAR Interim Results
Background: Worldwide, leflunomide is a commonly used Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It can be used as a monotherapy or in combination with other DMARDs to inhibit the production of inflammatory cells and accordingly reduce inflammation. Objectives: CLEAR is a multi-centric study that aims to assess the clinical efficacy and safety of leflunomide as first-line and/or add-on therapy to other DMARDs with or without steroids in Egyptian patients with active Rheumatoid Arthritis (RA). Methods: Egyptian patients with active RA for whom leflunomide was prescribed at physicians’ discretion were observed for 12 weeks. Clinical Disease Activity Index (CDAI) score, and Health Assessment Questionnaire Disability Index (HAQ-DI) score were acquired thrice during this period. This study was registered on clinicaltrials.gov (NCT03599986). Results: Interim analysis of the data collected from 337 patients (in 21 centers) showed a statistically significant decrease in the mean total CDAI score throughout the first 12 weeks of treatment (pp<0.001) was also observed in HAQ-DI, as the mean ±SD score decreased from 1.46 ±0.69 at baseline to reach 0.67 ±0.54 at week 12 (% reduction: 56.11 ±27.59). Conclusion: Results of the interim analysis suggest that treatment of Egyptian patients with active RA with leflunomide (as first-line and/or add-on therapy to other DMARDs with or without steroids) for 12 weeks may be effective in terms of CDAI score and HAQ-DI score reduction and may offer an alternative for patients who experienced resistance, inadequate response or intolerance to other DMARDs.